Healthcare ETFs: XLV, IBB, and Sector Investment Vehicles
Which Healthcare ETF Fits Your Investment Objective?
Healthcare ETFs span a wide spectrum from broad sector exposure (XLV covering all Healthcare subsectors) to pure biotech plays (IBB and XBI) to device-focused and managed care-focused alternatives. Understanding which Healthcare ETF provides which subsector exposure — and the concentration risks within each — enables investors to construct Healthcare allocations precisely aligned with their investment thesis rather than accepting the concentration profile of any single ETF.
Quick definition: Healthcare ETFs range from broad sector coverage (XLV includes pharmaceuticals, devices, managed care, and biotech in S&P 500 weighting) to subsector-specific (IBB tracks a modified market-cap biotech index; XBI is equal-weight biotech; IHI focuses on medical devices; IHF focuses on managed care/facilities) — with each vehicle emphasizing different subsector risk-return profiles.
Key takeaways
- XLV (SPDR Healthcare ETF) is the broadest and most liquid Healthcare sector ETF — approximately $35+ billion in AUM — but UnitedHealth Group alone represents approximately 8–10% of the portfolio
- IBB (iShares Biotech ETF) tracks a modified market-cap-weighted biotech index with significant concentration in large commercial biotech (Amgen, Gilead, Regeneron, Vertex) — less volatile than pure development-stage biotech
- XBI (SPDR S&P Biotech ETF) is equal-weight across approximately 130+ biotech companies — providing diversified exposure to development-stage biotech with high volatility and high return potential
- IHI (iShares US Medical Devices ETF) provides focused device sector exposure — useful for investors with specific views on procedure volumes and device innovation cycles
- Healthcare ETF selection should be driven by which Healthcare thesis the investor holds: defensive income (XLV), biotech innovation (XBI/IBB), device growth (IHI), or managed care (managed care-focused vehicles)
XLV: the broad healthcare benchmark
Construction: XLV tracks the S&P Healthcare Select Sector Index, which includes all Healthcare companies from the S&P 500. This provides large-cap Healthcare exposure across all subsectors proportional to S&P 500 market cap weights.
UnitedHealth Group dominance: UnitedHealth Group's approximately $500+ billion market cap makes it the largest healthcare company in the US — representing approximately 8–10% of XLV. This means XLV performance is significantly driven by UnitedHealth's stock performance. When UnitedHealth faces regulatory headwinds (CMS rate cuts, MLR pressure) or positive catalysts (membership growth, Optum expansion), XLV moves disproportionately relative to its stated diversification.
Top 10 concentration: XLV's top 10 holdings typically represent approximately 55–65% of the ETF. After UnitedHealth, the next largest weights are typically Eli Lilly (approximately 8–10%, rising with GLP-1 appreciation), Johnson & Johnson (approximately 6–8%), AbbVie (approximately 5–7%), Merck (approximately 5–6%), and Thermo Fisher/Abbott/Danaher (approximately 3–5% each).
Eli Lilly's growing weight: As Eli Lilly's market cap grew approximately 4x from 2020 to 2024 due to GLP-1 drug enthusiasm, its XLV weight grew proportionally from approximately 2–3% to approximately 8–10%. XLV investors in 2020 who expected broad Healthcare exposure found themselves increasingly exposed to GLP-1 drug company dynamics as Lilly's weight grew.
Expense ratio: 0.09% — competitive for a large, liquid sector ETF.
Use case: XLV is appropriate for broad Healthcare sector exposure with S&P 500-proportional subsector weighting. The default vehicle for tactical Healthcare overweighting or underweighting relative to S&P 500 benchmark.
IBB: large commercial biotech exposure
Construction: IBB (iShares Biotechnology ETF) tracks the NYSE Arca Biotechnology Index — a modified market-cap-weighted index of biotech companies. The modification includes a cap on single-company weight and minimum liquidity requirements.
Large commercial biotech emphasis: IBB's top holdings are typically the largest commercial biotech companies: Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and BioNTech/Moderna (during COVID-era), plus some larger development-stage companies. This profile makes IBB less volatile than pure development-stage biotech exposure.
Moderate development-stage exposure: IBB includes some development-stage companies but their lower market caps mean they are small weights in the portfolio — IBB's largest holdings are commercial-revenue generating companies whose performance depends on existing product revenue and pipeline progression.
AUM and liquidity: IBB typically has $7–12+ billion in assets — highly liquid for institutional positioning.
Expense ratio: 0.45% — higher than broad sector ETFs, reflecting the specialized focus.
XBI: equal-weight development-stage biotech
Construction: XBI (SPDR S&P Biotech ETF) tracks the S&P Biotechnology Select Industry Index — an equal-weight index of approximately 130+ biotech companies. Each company has approximately equal weight regardless of market cap.
Development-stage biotech dominance: Equal weighting means small development-stage biotech companies have the same weight as large commercial companies. This provides genuine exposure to the binary risk-return profile of clinical-stage biotech — which IBB dilutes through large-cap commercial biotech concentration.
Volatility profile: XBI is one of the more volatile large ETFs in the market — approximately 40–60% annualized volatility versus approximately 15–18% for the S&P 500. The equal weighting means development-stage biotech failures and successes have material ETF impact.
Return distribution: XBI's equal weighting creates a different return distribution than IBB — during biotech bull markets (2020–2021), XBI significantly outperformed IBB as small-cap biotech surged on COVID-era enthusiasm and capital availability; during bear markets (2022), XBI underperformed IBB as small-cap biotech was hit harder by rate rises and capital constraints.
Use case: XBI is appropriate for investors who want genuine biotech innovation exposure (including development-stage companies) and can tolerate high volatility. Inappropriate as defensive Healthcare allocation.
How it flows
IHI: medical device ETF
Construction: IHI (iShares US Medical Devices ETF) tracks the Dow Jones US Select Medical Equipment Index — focusing on medical device and equipment companies.
Key holdings: IHI typically holds Abbott Laboratories, Intuitive Surgical, Becton Dickinson, Stryker, Edwards Lifesciences, Baxter International, Boston Scientific, Zimmer Biomet, and other device companies. The ETF provides pure-play device sector exposure without pharmaceutical or managed care dilution.
Procedure volume thesis: Investors who want to express a specific view on elective procedure volume recovery (post-COVID normalization) or demographic-driven orthopedic and cardiac device demand can use IHI for targeted exposure.
Lower volatility than biotech: Device revenue is more predictable (procedure volume driven) than drug approval binary outcomes — IHI is less volatile than XBI while still providing healthcare growth exposure.
Thematic healthcare ETFs
Genomics and precision medicine ETFs: Several ETFs focus on genomics companies (ARKG from ARK Invest was the prominent example — though its performance in 2021–2022 illustrated the speculative risk of early-stage genomics themes at excessive valuations).
Digital health ETFs: Healthcare technology, telehealth, and digital health companies are covered by specialty ETFs — these tend toward higher-growth, higher-valuation profiles with less defensiveness.
Dividend-focused healthcare: Some dividend-oriented Healthcare ETFs weight toward high-yield healthcare companies (managed care companies with dividends, large pharmaceutical companies with consistent dividends) while de-emphasizing non-dividend paying biotech.
Comparing expense ratios and liquidity
| ETF | Strategy | AUM | Expense Ratio | Volatility |
|---|---|---|---|---|
| XLV | Broad sector large cap | $35B+ | 0.09% | Low-moderate |
| VHT | Broad sector (Vanguard) | $17B+ | 0.10% | Low-moderate |
| IBB | Large commercial biotech | $8B+ | 0.45% | Moderate |
| XBI | Equal-weight development biotech | $5B+ | 0.35% | Very high |
| IHI | Medical devices | $3B+ | 0.40% | Moderate |
Combination approaches
Institutional investors often combine Healthcare ETFs to achieve specific sector profiles:
Defensive with biotech overlay: XLV (core defensive exposure) + XBI or IBB (biotech innovation upside) creates a combination that captures Healthcare's defensive characteristics while adding biotech innovation optionality.
Device focus without pharma: IHI + managed care holdings provides Healthcare exposure without large pharmaceutical company weighting.
Avoiding managed care: For investors with negative views on managed care (Medicare Advantage reimbursement risk, MLR pressure), combining pharma-specific ETFs with IHI and limited managed care weight creates a Healthcare allocation that de-emphasizes the insurance model.
Common mistakes
Using XBI as a defensive Healthcare allocation. XBI's equal-weight development-stage biotech exposure is among the highest-volatility large-ETF strategies available — appropriate for innovation-seeking investors but completely wrong for recession-defensive Healthcare positioning. XBI declined approximately 50% in 2022 versus XLV's approximately 5% decline.
Ignoring UnitedHealth and Eli Lilly concentration in XLV. These two companies together often represent 18–22% of XLV — creating concentration risk similar to the Amazon/Tesla issue in Consumer Discretionary. Investors who expect "broad Healthcare exposure" from XLV should understand that they are significantly expressing views on these specific companies.
FAQ
What is the difference between IBB and XBI?
IBB is market-cap weighted with a focus on larger commercial biotech companies (Amgen, Gilead, Regeneron, Vertex) — providing moderate biotech exposure without extreme development-stage concentration. XBI is equal-weight across approximately 130+ biotech companies, giving significant weight to development-stage companies. IBB is less volatile and more defensive within biotech; XBI is higher risk/return with development-stage binary outcomes. Current holdings and performance data for both ETFs is available from iShares at ishares.com and SPDR at ssga.com.
Related concepts
- Healthcare Overview
- Healthcare Historical Performance
- Healthcare Portfolio Sizing
- Pharmaceutical and Biotech Analysis
- Medical Devices Analysis
Summary
Healthcare ETF selection should be driven by specific investment thesis: XLV (broad defensive Healthcare with S&P 500 proportional weighting, approximately $35B+ AUM, 0.09% expense ratio) for general sector exposure; IBB for large commercial biotech exposure with moderate volatility; XBI for equal-weight development-stage biotech with high volatility and high return potential; IHI for device-sector-specific procedure volume themes. XLV's UnitedHealth and Eli Lilly concentration (approximately 18–22% combined) creates single-stock risks that investors should understand before assuming broad defensive exposure. XBI is completely inappropriate for defensive Healthcare positioning — its equal-weight development-stage structure creates extraordinary volatility. Combination approaches (XLV core + XBI or IBB overlay for biotech innovation) allow investors to customize their Healthcare subsector profile beyond any single ETF's construction.